Search

Certara Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

6.81 -2.44

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

6.77

Max

6.99

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-2.9M

-8.8M

Pardavimai

3.3M

107M

P/E

Sektoriaus vid.

100.714

60.149

Pelnas, tenkantis vienai akcijai

-0.06

Pelno marža

-8.196

Darbuotojai

1,515

EBITDA

-16M

16M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+12.41% upside

Dividendai

By Acuity

Kitas uždarbis

2026-08-04

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

258M

1.1B

Ankstesnė atidarymo kaina

9.25

Ankstesnė uždarymo kaina

6.81

Naujienos nuotaikos

By Acuity

19%

81%

32 / 340 reitingas Healthcare

Certara Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-07-20 19:31; UTC

News

Certara Inc partners with NVIDIA to enhance its AI biosimulation platform. Shares are higher, reflecting positive market sentiment around the collaboration.

Akcijų palyginimas

Kainos pokytis

Certara Inc Prognozė

Kainos tikslas

By TipRanks

12.41% į viršų

12 mėnesių prognozė

Vidutinis 7.79 USD  12.41%

Aukščiausias 10 USD

Žemiausias 6 USD

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Certara Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

9 ratings

3

Pirkti

6

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

32 / 340 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Certara Inc

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
help-icon Live chat